AZP 531

Drug Profile

AZP 531

Alternative Names: AZP-531

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alize Pharma
  • Class Antihyperglycaemics; Cyclic peptides; Peptide hormones
  • Mechanism of Action Ghrelin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Prader-Willi syndrome
  • Preclinical Ischaemia
  • No development reported Type 2 diabetes mellitus

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus in United Kingdom (SC)
  • 18 Jul 2016 Alize Pharma has patent protection for its unacylated ghrelin analogues and its therapeutic applications
  • 26 Apr 2016 Top-line efficacy and safety data from a phase II trial in Prader-Willi syndrome released by Alize Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top